Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19 LEARN MORE PFIZER INVESTS $120MIL IN BIOTECH INNOVATION LEARN MORE Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 LEARN MORE AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE LEARN MORE RECENT PRESS RELEASES 05/05/2021 - PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS 28/04/2021 - Pfizer Acquires Amplyx Pharmaceuticals 22/04/2021 - Pfizer Declares Second-Quarter 2021 Dividend 08/03/2021 - Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate 04/03/2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 03/03/2021 - U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer 26/02/2021 - European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older 26/02/2021 - EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency 25/02/2021 - Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants 23/02/2021 - U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine) 22/02/2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 19/02/2021 - Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA 17/02/2021 - Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids 17/02/2021 - Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women 17/02/2021 - Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page Next › Last page Last »